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ABSTRACT
The RhaS and RhaR proteins are transcription activators that respond to the
availability of L-rhamnose and activate transcription of the operons in the E. coli L-
rhamnose catabolic regulon.  RhaR activates transcription of rhaSR, and RhaS activates
transcription of the operon that encodes the L-rhamnose catabolic enzymes, rhaBAD, as
well as the operon that encodes the L-rhamnose transport protein, rhaT.  RhaS is 30%
identical to RhaR at the amino acid level and both are members of the AraC/XylS
family of transcription activators.  The RhaS and RhaR binding sites overlap the –35
hexamers of the promoters they regulate, suggesting they may contact the s70 subunit of
RNA polymerase as part of their mechanisms of transcription activation.  In support of
this hypothesis, our lab previously identified an interaction between RhaS residue D241
and s70 residue R599.  Here, we first identified two positively charged amino acids in
s70, K593 and R599, and three negatively charged amino acids in RhaR, D276, E284, and
D285, that were important for RhaR-mediated transcription activation of the rhaSR
operon.  Using a genetic loss-of-contact approach we have obtained evidence for a
specific contact between RhaR D276 and s70 R599.  Finally, previous results from our lab
separately showed that RhaS D250A and s70 K593A were defective at the rhaBAD
promoter.  Our genetic loss-of-contact analysis of these residues indicates that they
identify a second site of contact between RhaS and s70.
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INTRODUCTION
Transcription activation in Escherichia coli often involves the interaction of a
DNA-binding activator protein with one of the subunits of RNA polymerase (RNAP),
most often the sigma (s) or alpha (a) subunit.  Transcription activators that bind
immediately upstream and adjacent to RNAP, in some cases overlapping the –35
promoter hexamer, may interact with the C-terminal domain (domain 4) of the s
subunit of RNAP (8, 27).  The cI protein of bacteriophage l  is required for the
establishment and maintenance of lysogeny and is perhaps the best-characterized
example of a transcription activator that contacts s70.  The lcI protein activates
transcription of the PRM promoter when bound at the OR2 operator site, which overlaps
the PRM –35 hexamer by 2 bp (30).  Current evidence suggests that s70 residues R588,
K593, and R596 are required for activation by lcI (23, 26, 35).  Genetic and molecular
modeling studies as well as the recent structure of a ternary lcI/s domain 4/DNA
complex indicate that lcI D38 contacts both s70 K593 (sA K418) and R596 (sA R421), and
lcI E34 contacts s70 R588 (sA R413) (8, 19, 26, 35).  Prior to the ternary complex structure,
a molecular model of the interaction indicated that s70 K593 (sA K418) contacts DNA but
was not positioned to contact lcI (6, 8, 35).  However, the ternary structure showed that
the sA residue that aligns with s70 K593 has moved away from the DNA (relative to the
model of the interaction) and instead makes a protein-protein contact with lcI D38 (19).
There is also evidence that activation by several transcription activators in the
AraC/XylS family involves s70 domain 4.  Our lab previously identified two s70
residues, K593 and R599, which are required for full activation by RhaS, and further
obtained genetic evidence that s70 R599 is directly involved in a contact with RhaS D241
(4). These genetic results are also strongly supported by molecular modeling of the
RhaS-s70 complex on DNA (4).  Evidence for AraC interactions with s70 come from early
s70 mutants (eventually identified at R596) that increased araBAD expression in the
absence of activation by CRP (18, 39, 44) as well as the finding that araBAD expression
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in a Dcya strain was increased by s70 E591A and R596A and decreased by s70 K593A (27).
In addition, with a DNA that mimicked an open complex, a small amount of DNA
binding cooperativity could be detected between AraC and s70 (7).  At the melAB
promoter, genetic evidence indicated that s70 R596 interacts with MelR D261 and T265
while s70 R599 also interacts with MelR D261, which aligns with RhaS D241 (16).  The
Ada protein has two activation domains, one of which is an AraC/XylS family domain
which is required to activate transcription of the alkA operon (33).  Alanine substitutions
of s70 residues K593, K597 and R603 each had significant defects in Ada-dependent alkA
transcription in vivo and in vitro (24).
The transcription activator RhaS, and the closely related RhaR protein, activate
transcription of the E. coli L-rhamnose catabolic operons in the presence of the sugar L-
rhamnose (10, 11, 42).  RhaS activates transcription of the rhaBAD and rhaT operons by
binding as a dimer to sites that overlap the –35 hexamers of the promoters by four base
pairs and extend upstream to –81 and –82, respectively (Fig. 1 for rhaBAD promoter)
(10, 45).  Similarly, RhaR activates transcription of the rhaSR operon by binding as a
dimer to a site that overlaps the RNAP binding site by four base pairs and extends
upstream to –82 (Fig. 1) (43).  The long binding sites for RhaS and RhaR each consist of
two 17 base pair imperfect inverted repeat half sites that are separated by 16 or 17 base
pairs of uncontacted DNA (10, 43, 45).  Each RhaS and RhaR monomer is predicted to
contain two helix-turn-helix DNA binding motifs and thereby contact two consecutive
major grooves of DNA (38).  The cyclic AMP receptor protein (CRP) also activates
transcription at all three of the rha promoters.  At the rhaBAD and rhaT promoters, the
CRP binding site is located immediately upstream of the RhaS binding site and is
centered at –92.5 and –93.5, respectively (Fig. 1 for rhaBAD promoter) (11, 45).  The CRP
site required for full activation at rhaSR is located upstream but not adjacent to the
RhaR binding site and is centered at –111.5 (Fig. 1) (17).
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RhaS and RhaR are members of a subset of the AraC/XylS family that share
amino acid sequence similarity with AraC over its entire length (9, 13, 28).  Based on
this similarity, RhaS and RhaR are predicted to consist of two domains connected by a
flexible linker (5, 12, 29, 41).  The N-terminal domains are predicted to be responsible
for L-rhamnose-binding and dimerization, while the C-terminal domains contain the 99
amino acid region that classifies them as members of the AraC/XylS family.  In all
studied cases of AraC/XylS family members, including RhaS and RhaR, the
characteristic 99 amino acid region constitutes a DNA binding domain (3, 10, 43).  This
DNA-binding domain has also been shown to be involved in transcription activation in
a number of AraC/XylS family proteins including Ada, RhaS, AraC, MelR, MarA, SoxS,
XylS, and UreR (1, 4, 5, 15, 16, 20-22, 37).
In this paper, we further explored the mechanisms of transcription activation by
RhaR and RhaS.  We identified amino acids residues in the C-terminal domain of s70
and in RhaR that are important for RhaR-mediated transcription activation at the rhaSR
promoter.  We then used a genetic loss-of-contact approach to identify an interaction
between RhaR D276 and s70 R599 that is required for RhaR-mediated activation.  We
also extended the previous studies by Bhende and Egan (4) of RhaS-mediated
transcription activation at rhaBAD.  Here we identified a second interaction between
RhaS and s70, in this case, RhaS D250 and s70 K593.
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MATERIALS AND METHODS
Culture media and conditions.  E. coli cultures for b-galactosidase assays were
grown in MOPS buffered medium (4, 34).  Tryptone-yeast extract (TY) liquid medium
(0.8% tryptone; 0.05% yeast extract; and 0.05% NaCl) was used to grow cells for most
other experiments.  SacB selection media (1% tryptone; 0.5% yeast extract; 1.5% agar;
and 5% sucrose; pH 7.8) was used to select against sacB+ strains (14).  Antibiotics were
used as indicated at the following concentrations: ampicillin (200 mg/ml),
chloramphenicol (25 mg/ml), kanamycin (25 mg/ml), and tetracycline (20 mg/ml).
General Methods.  Standard methods were used for restriction endonuclease
digestion and ligation using restriction endonucleases and T4 DNA ligase purchased
from New England Biolabs (Beverly, MA).  Transformation was carried out using
chemically induced competent cells of E. coli and plasmid DNA was purified by
alkaline lysis.  DNA sequencing reactions were carried out using custom-synthesized
IRD41 dye-labeled primers (Table 2) from LI-COR Inc. (Lincoln, NE) and the Thermo
Sequenase primer cycle sequencing kit from Amersham Life Sciences (Arlington
Heights, IL).  DNA sequences were analyzed by automated di-deoxy sequencing on a
LI-COR 4000L sequencer (University of Kansas Biochemical Research Service
Laboratory).  The Expand High Fidelity PCR System (Roche; Indianapolis, IN) was used
to amplify DNA fragments for cloning as well as to generate template for DNA
sequencing from rhaS and rhaR alleles that were recombined into the chromosome.  The
DNA sequence of both strands was determined for the entire cloned region of all
cloned, mutagenized, and recombined DNA fragments.  The QIAquick PCR
Purification Kit (Qiagen; Chatsworth, CA) was used to clean up PCR products.
Strains, plasmids and phage. Table 1 lists the strains, phage, and plasmids used
in this study.  All strains used in b-galactosidase assays were derived from ECL116 (2)
and carried lacZ fusions in single copy on l phage integrated at attl (40).  P1 phage-
mediated generalized transduction was used to move D(recC ptr recB recD)::Plac-bet exo
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kan (from KM22) into SME1216 (selecting for kanamycin resistance) to make SME2417.
SME2495 was made using P1 transduction to move D(rhaSR)::kan zih-35::Tn10 (from
SME2800) in SME1217 selecting for tetracycline resistance and then screening for a Rha-
phenotype.  SME2496 was made from SME2416 by transformation with a PCR product
containing D(rhaSR)::cat-sac (amplified from pSE254 – described below), which was
recombined onto the chromosome using the recombination genes of bacteriophage l
(encoded by D(recC ptr recB recD)::Plac-bet exo kan)(31).  The plasmid pSE250 was made
by restriction endonuclease digestion of pSE101 with BamHI at the rhaT’ end of the
clone and EcoRI (a natural site within the rhaBAD promoter) creating the fragment
rhaSRT’, which was purified from an agarose gel using Qiagen’s QIAEX Gel Extraction
Kit.  The rhaSRT’ fragment was then ligated to pUC18 (46) which had been digested
with BamHI and EcoRI.  To make pSE254, long-way around PCR using pSE250 as
template and primers 2297 and 2298 amplified all of the pSE250 sequence except rhaSR
and added a BglII site at each end.  Then PCR with primers 2299 and 2300, using a PCR
product containing the cat-sac cassette (provided by Kenan Murphy (32)) as template,
generated a product that was ligated to the BglII sites of the long-way around PCR
product to create pSE254.  Plasmids pML148-169 (containing mutations in the rpoD
gene) were obtained from the laboratory of Carol Gross and were sequenced to ensure
they still carried the expected mutations.  Several of the rpoD alleles were initially found
to be wild-type.  Assays involving these alleles were repeated upon obtaining true
mutants.
Mutagenesis of rhaS and rhaR.  The mutant rhaS D250A allele was moved from
pSE172 into the context of pSE101 by digesting pSE172 with BstEII and BglII (both sites
are native to the wild-type rhaS gene) to create a fragment encoding the RhaS D250A
substitution.  This fragment was then ligated to similarly digested pSE101 to make
pSE249.  Genes encoding alanine substitution derivatives of RhaR D276A and RhaR
D285A were constructed by oligonucleotide-directed mutagenesis of rhaR in pGEM-
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11Zf(+) (Promega; Madison, WI) using the GeneEditor kit (Promega) and
oligonucleotides 2208 and 2210.  The mutant rhaR alleles were then subcloned to pSE250
using NheI and SmaI restriction endonuclease sites (both sites occur naturally within
rhaR) to make pSE251 and pSE253.  The rhaR E284A mutagenesis was performed using
PCR to make oligonucleotide-directed mutations at the desired position with primer
2381, which also contained the recognition sequence for the EarI restriction
endonuclease.  Second, a non-mutagenized PCR fragment was made, also using a
primer with EarI restriction sites.  Finally, ligation of the mutant and wild-type DNA
fragments allowed seamless reconstruction (25) of the full-length rhaR E284A gene in
the context of rhaSRT’ to make pSE252.  Oligos Etc (Wilsonville, OR), Integrated DNA
Technologies (Coralville, IA), and MWG-Biotech (High Point, NC) synthesized
oligonucleotide primers used in mutagenesis (Table 2).  Mutations were initially
identified by diagnostic PCR using the following method.  The very 3’ nucleotides of
the diagnostic oligonucleotide contained the desired substitution(s) such that
amplification was only possible (in combination with a suitable downstream primer)
when the template DNA carried the desired mutation.  Putative mutants identified by
this method were confirmed by DNA sequencing of both strands of the entire cloned
region (see Table 2 for sequencing oligonucleotides).
Recombination of rhaS and rhaR alleles onto the chromosome.  The mutant
rhaS and rhaR alleles constructed as described above were recombined onto the E. coli
chromosome such that they replaced the wild type rhaS or rhaR alleles using the
following methods.  Each rhaS or rhaR mutant was present on a plasmid in the context
of rhaSRT’ (pSE249, pSE251, pSE252, and pSE253).  Oligonucleotides 1170 and 2292
were used to amplify each mutant rhaSRT’ region by high-fidelity PCR.  Approximately
500 ng of the rhaSRT’ PCR product carrying a mutant allele was used to transform
either SME2495 [l (FrhaB-lacZ) D110, D(recC ptr recB recD)::Plac-bet exo kan,
D(rhaSR)::kan, zih-35::Tn10] or SME2496 [l F(rhaB-lacZ) D110, D(recC ptr recB recD)::Plac-
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bet exo kan, D(rhaSR)::cat-sac, zih-35::Tn10].  Since SME2495 and SME2496 both contained
Plac-bet exo, which encodes the l phage recombination proteins, the frequency of
homologous recombination was much higher in these strains than in wild-type E. coli
strains (31).  The transformants were screened by spread plating on media containing X-
gal (40mg/ml) and L-rhamnose (0.2%) to identify functional, or partially functional,
rhaSR genes that replaced the D(rhaSR) allele.  There was no selection for successful
recombinants in SME2495, rather we screened for blue colonies amongst a lawn of
white colonies.  When transforming SME2496, which contains a cat-sacB cassette (32) in
place of rhaSR, we selected for the sucrose resistance of cells that had lost the sacB gene
(which confers sucrose sensitivity) by homologous recombination.  However, due to a
significant background of spontaneous sucrose resistant mutants, the transformants
were also screened for at least partially functional rhaS or rhaR genes by adding X-gal
(40mg/ml) and L-rhamnose (0.2%) to the SacB selection plates.  We found that sucrose
inhibition of the sacB+ cells worked most reproducibly at room temperature, although it
took about 3 days for the cells to grow.  Phage P1-mediated generalized transduction
was then used to transfer the rhaS or rhaR allele of interest (linked to zih-35::Tn10)  to
either 1851 [l F(rhaB-lacZ) D84] or 2515 [l F(rhaS-lacZ) D92] by selecting for the
tetracycline resistance conferred by zih-35::Tn10.  Diagnostic PCR, as described above,
was used to initially identify transductants that contained the rhaS or rhaR mutation of
interest.  High fidelity PCR was then used to amplify rhaSRT’ from the chromosome
using oligonucleotides 2097 and 1170, and the entire 3kb PCR product was sequenced,
as described above, to verify the presence of the desired mutation with no additional
mutations.  Phage P1-mediated transduction was then used to introduce recA::kan into
each strain to make SME2689, 2691, 2692, and 2933.  Finally, competent cells of each
strain were made and transformed with plasmids containing either the wild type-,
K593A-, L595A-, R599A-, or R608A-encoding s70 genes for b-galactosidase assays.
10
b-Galactosidase assay.  b-galactosidase assays were performed as previously
described (3).  In all cases, chromosomal rpoD was expressed from its own promoter,
not the trp promoter described in Lonetto et al. (27), and the plasmid encoded s70
derivatives were expressed in the absence of IPTG.  Under these conditions, the s70
derivatives are expected to account for approximately 50% of the total s70 in the cells
(27).  Specific activities were averaged from at least three independent assays with two
replicates in each assay.  The assays were performed on at least two different days, with
independent cell growth steps (starter TY culture, overnight culture, and final growth
culture) for each assay.
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RESULTS
s70 derivatives at the rhaSR promoter.  We wished to determine whether any
residues near the C-terminal end of s70 were important for transcription activation by
RhaR.  Lonetto et al. (27) constructed a library of alanine substitutions at 17 different
positions near the C-terminus of s70 and found that some substitutions resulted in
defects at class II activator-dependent promoters.  Previous work from our lab found
that two of the alanine substitutions in this library were defective at a truncated rhaBAD
promoter where RhaS was the only transcription activator (4).  We assayed this library
of alanine substitutions in s70 at two RhaR-activated single-copy translational fusions,
F(rhaS-lacZ)D216 and F(rhaS-lacZ)D92.  The F(rhaS-lacZ)D216 promoter contained the
RhaR binding site as well as upstream CRP sites, while the F(rhaS-lacZ)D92 promoter
contained only the RhaR binding site (Fig. 1).  Since the assays were carried out in a
strain that also expressed wild-type s70 from the chromosome (27), we considered
values below 80% of wild-type activity to be significant defects.  At F(rhaS-lacZ)D216,
s70 derivative L595A had 66% of the activity of wild-type s70 (Fig. 2A), while the
remaining s70 derivatives were not significantly defective.  When the same sigma
derivatives were assayed at F(rhaS-lacZ)D92, L595A was still significantly defective,
with 53% activity compared to wild-type s70 (Fig. 2B).  In addition, three alanine
substitutions of positively charged amino acid residues, K593A (79%), R599A (48%),
and R608A (77%) were defective at F(rhaS-lacZ)D92.  These results suggested that s70
residues K593, L595, R599, and R608 might make protein-protein contacts with RhaR
that are required for transcription activation.  The lack of defect by s70 K593A, R599A, or
R608A at the F(rhaS-lacZ)D216 promoter is similar to previous findings with RhaS and
AraC that substitutions at some s70 residues were only defective in the absence of CRP
activation (4, 27).
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Based on the previous finding in our lab that a contact between RhaS residue
D241 and s70 residue R599 is required for full transcription activation by RhaS (4), we
predicted that RhaR D276, which aligns with RhaS D241 (Fig. 3), might contact s70 R599
at the rhaSR promoter.  Molecular modeling of the RhaR-s70 interaction (Fig. 4) indicates
that the negatively charged RhaR residue D276 is very close to the positively charged
s70 residue R599.  RhaR D276 is also near s70 R608, although in the model they do not
appear close enough to interact.  The molecular model further shows that two adjacent
negatively charged RhaR residues, E284 and D285, were located near s70 K593.  Based
on these pieces of evidence, we hypothesized that contacts between some or all of the
RhaR residues D276, E284, and D285 and s70 might be required for maximal
transcription activation by RhaR.  We therefore tested alanine substitutions at these
positions in RhaR for defects in transcription activation.  
RhaR residues D276, E284, and D285 are important for rhaSR transcription
activation.  In order to test whether the side chains of RhaR residues D276, E284, and
D285 might play a role in transcription activation by RhaR, we constructed alanine
substitutions at each of these positions.  If the amino acid residues at these positions are
required for transcription activation, the alanine substitution should result in a
significant decrease in activation of rhaSR transcription.  To assay the RhaR derivatives,
the mutant rhaR alleles on plasmids were first recombined onto the chromosome such
that they replaced the wild-type rhaR gene (see Materials and Methods).  The wild-type
and mutant rhaR alleles were then assayed for activation of F(rhaS-lacZ)D92 (Fig. 5).
The results showed that all three of the alanine substitutions in RhaR were significantly
defective, highlighting the importance of the wild-type residues at those positions.  The
especially large defect of RhaR D285A may be partly due to a role in DNA-binding
based on its alignment with D250 in RhaS (Fig. 3), which makes base-specific contacts
with DNA (3).  However, a role in DNA-binding for RhaR D285 does not rule out
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interactions with s70, therefore all three of these RhaR residues are candidates for
specific contacts with s70.
Evidence for an interaction between RhaR D276 and s70 R599.  We used a
genetic loss-of-contact approach to test potential interactions between RhaR D276 and
s70 K593 or R599.  Using this approach, we separately combined wild-type RhaR or the
RhaR D276A derivative with each of three plasmids encoding either s70 wild-type,
K593A, or R599A in a strain carrying single copy F(rhaS-lacZ)D92.  The results shown in
Fig. 6A were graphed so that the activity with wild-type s70 was set to 100% for each
RhaR derivative, thereby illustrating the relative effects of each s70 derivative.  On this
graph, therefore, a s70 derivative that does not define a site of interaction with a given
RhaR derivative is expected to have the same relative defect when combined with the
indicated RhaR derivative as it does with wild-type RhaR, since the defects will be
independent of each other.  On the other hand, if a s70 derivative does define a site of
interaction with a given RhaR derivative, the s70 derivative will confer no further defect
when combined with the indicated RhaR derivative, since the interaction would already
have been lost with the RhaR derivative.  Using this method to analyze the results in
Fig. 6A, our first conclusion is that there is no interaction between RhaR D276 and s70
K593 since the s70 K593A derivative had approximately the same relative defect in
combination with either wild-type RhaR or RhaR D276A.  Therefore, the defects of s70
K593A and RhaR D276A are independent.  These results and those in Fig. 2B also show
that the s70 R599A derivative by itself (in a wild-type rhaR strain) had approximately
50% activity compared to wild-type s70.  However, when s70 R599A was combined with
RhaR D276A, the s70 R599A derivative conferred no further defect upon RhaR D276A.
In fact, the strain with the combination of s70 R599A and RhaR D276A had
approximately 1.7-fold higher activity than the strain with wild-type s70 and RhaR
D276A.  These results fit the criteria for an allele-specific contact between s70 R599 and
RhaR D276.  As mentioned above, molecular modeling is consistent with this
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interaction since RhaR D276 is in close proximity to s70 R599 in the model (Fig. 4).  We
also tested the s70 R608A derivative in combination with RhaR D276A and found that it
had the same relative defective as it did with wild-type RhaR (79% of wild-type s70
activity in both cases – not shown), therefore there was no indication of an interaction
between these two residues.
RhaR E284 and D285 and s70.  Using the same genetic loss-of-contact approach,
we also tested for potential interactions between s70 and RhaR E284 and D285.  The
results in Fig. 6B show that the K593A s70 derivative was not defective in combination
with RhaR D285A (104% of wild-type s70 activity), but the R599A s70 derivative also
became less defective (81% of wild-type s70 activity).  In the absence of the results with
s70 599A, one might conclude that RhaR D285 contacts s70 K593, since s70 K593A had no
significant defect when combined RhaR D285A, however, the lack of strict allele
specificity sheds doubt on this conclusion.  To further investigate the non-allele specific
defects of s70 substitutions in combination with RhaR D285A, we tested s70 L595A and
R608A derivatives, which were both defective in a wild-type rhaR strain, as shown in
Fig. 2B.  When combined with RhaR D285A, the s70 L595A and R608A derivatives were
not significantly defective with 86% and 87% of wild-type s70 activity, respectively (not
shown).  These results suggest that RhaR D285A may reduce the ability of RhaR to
interact with s70 in a non-allele specific manner; therefore, we can’t conclude whether
RhaR D285 contacts any of these s70 residues.
Fig. 6C shows the results of assays to identify potential interactions involving
RhaR E284.  Our results showed that neither s70 K593A nor R599A conferred a
significant defect on RhaR E284A.  In fact, the s70 K593A-RhaR 284A combination gave
much higher activity (362%) than the RhaR 284A derivative with wild-type s70.
Therefore, as above, we tested the s70 L595A and R608A derivatives in the rhaR E285A
strain and measured 139% and 93% activity , respectively, compared to wild-type s70
(not shown).  Thus, we again found that all four of the s70 derivatives that were
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defective in the wild-type rhaR strain were no longer significantly defective in the rhaR
E284A strain.  These results suggest that, similar to RhaR D285A, the RhaR E284A
derivative may reduce the ability of RhaR to interact with s70 in a non-allele specific
manner.  One explanation for the very high relative activity of RhaR E284A in
combination with s70 K593A is that a new interaction may have been created in this
case.
Evidence for a specific interaction between RhaS D250 and s70.  Our lab
previously identified an interaction between RhaS D241 and s70 R599, and we also
found that s70 K593A was defective at F(rhaB-lacZ)D84 but did not identify an amino
acid in RhaS that might contact s70 K593 (4).  The molecular model in Fig. 4 shows that
the only negatively charged RhaS residue that is in close proximity to the positively
charged s70 K593 is RhaS D250, suggesting that these two residues might make a
contact.  Previous results from our lab showed that RhaS D250A was 12-fold defective
for F(rhaB-lacZ)D84 activation, however, they also indicated that this residue
participates in a base-specific DNA contact (3).  In contrast to other approaches to
identify positive control mutants, the genetic loss-of-contact approach does not require
that the protein have wild-type DNA-binding capability, hence it has the potential to
identify residues that have dual DNA-binding and transcription activation functions.
We therefore used the genetic loss-of-contact approach to test whether RhaS D250 and
s70 K593 might be involved in an interaction.  The results (Fig. 6D) support the
hypothesis of an interaction between RhaS D250 and s70 K593 since the K593A
derivative was not significantly defective when combined with RhaS D250A (87%
activity compared to wild-type s70).  However, when s70 R599A was combined with
RhaS D250A, it maintained approximately the same relative defect as it had with wild-
type RhaS.  These results suggest that there is an allele-specific interaction between
RhaS D250 and s70 K593.  Molecular modeling is consistent with this interaction since,
as mentioned above, RhaS D250 is in close proximity to s70 K593 in the model (Fig. 4).
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DISCUSSION
The C-terminus of s70 is important for RhaS- and RhaR-mediated transcription
activation.  The binding sites for both RhaS and RhaR overlap the –35 region of their
respective core promoters by four base pairs placing them in ideal positions to interact
with the s70 subunit of RNAP.  Previous results by Bhende and Egan (4) identified two
amino acid residues in s70, K593 and R599, that were important for RhaS-mediated
transcription activation at rhaBAD and rhaT.  In this study, we identified four amino
acid residues in s70, K593, L595, R599, and R608 which were important for RhaR-
mediated transcription activation of rhaSR (Fig. 2B).  Two of the alanine substitutions in
s70, K593A and R599A, were defective at all three of the rha promoters suggesting
similar mechanisms of activation by RhaS and RhaR.
The results in this paper (Fig. 2) as well as those from the previous study (4)
showed that s70 K593A and R599A were only defective at truncated rha promoters that
did not include the upstream CRP binding sites.  This is similar to the findings at
several other promoters that require multiple activators, such as araBAD, uhpT and narG
(18, 27, 36, 39).  Two possible explanations for this trend are that the second activator
increases the total number of interactions such that the relative importance of each
individual interaction decreases, or that the second activator creates redundancies in
activation that mask the importance of other interactions.  A third possibility is that the
second activator alters the orientation of the first activator relative to s70 such that the
primary activator is no longer in an ideal position to interaction with s70.  In the first
two models, the activator interaction with s70 occurs both in the presence and absence of
the second activator, but can only be detected in its absence, whereas in the third model,
the interaction between the first activator and s70 only occurs in the absence of the
second activator.  Further experiments will be needed to distinguish these models.  At
the rhaSR promoter, the s70 L595A derivative was unique in that it was defective both in
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the presence and absence of the second activator, CRP, but it’s role in RhaR-mediated
transcription activation is not yet known.
Specific amino acid contacts between s70 and RhaR.  Previous results showing
an interaction between RhaS D241 and s70 R599 at rhaBAD (4) led us to investigate
whether an interaction between RhaR D276 and s70 R599 might be required for RhaR
activation at rhaSR.  We also used a molecular model of the RhaR-s70 domain 4
interaction in which the structure of MarA (38) represented RhaR (Fig. 4), to identify the
only two negatively charged RhaR residues, E284 and D285, that were near s70 K593.
RhaR E284 and D285 were therefore considered candidates for residues that might
interact with s70 K593.  After determining that alanine substitutions at RhaR residues
D276, E284, and D285 were all defective for rhaSR activation (Fig. 5), we used a genetic
loss-of-contact approach to test for specific amino acid interactions between s70 and
RhaR.
To carry out a loss-of-contact analysis, one must first identify defective
derivatives of each of the potentially interacting proteins.  In the simplest case, the full
defect of both of the two interacting residues is due to loss of the interaction – in other
words, the only role of the two residues is the interaction.  The rationale behind this
approach in this simple case is that mutation of one or the other of the interacting
residues will eliminate the interaction, therefore, the phenotype of a strain carrying both
mutations will be the same as the phenotype of the strains carrying the individual
mutations.  If one of the residues has a second role in addition to the interaction, then
the strain carrying both mutations will have a phenotype that is no worse than the more
defective of the strains carrying the two individual mutations.  This analysis does not
provide conclusive results if both residues have roles in addition to the interaction.  It is
also expected that the predicted interactions will be allele specific.  The majority of
combinations of defective derivatives are not expected to identify interacting residues;
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and in these cases the defects resulting from each of the two mutations will at least be
additive.
Using this rationale to interpret our genetic loss-of-contact assays, the results in
Fig. 6A provide evidence for an interaction between s70 R599 and RhaR D276.  This
result is similar to previous results from our lab (4) that indicate an interaction between
s70 R599 and RhaS D241 and evidence from Grainger et al. that s70 R599 interacts with
MelR D261 (16), which aligns with RhaS D241 and RhaR D276.  Molecular modeling of
the RhaR-s70 complex (Fig. 4) shows that s70 R599 and RhaR D276 are in close
proximity, consistent with our interpretation that these two residues interact.  Our
genetic loss-of-contact results do not provide evidence for an interaction between s70
K593 and RhaR E284 or D285 (Fig. 6C).  Instead, our results indicate that alanine
substitutions at RhaR E284 and D285 result in non-allele specific decreases in the defects
of all of the s70 alleles tested.  One hypothesis is that RhaR E284A and D285A alter the
details of the RhaR DNA interaction such that RhaR is no longer in an ideal position to
interact with s70 domain 4.
The role of s70 K593 in transcription activation by RhaS.  Residue K593 of s70
has been found to be important for several transcription activators, including AraC,
UhpA, lcI, FNR, Ada, RhaR (this study), and RhaS (4, 24, 27, 35, 36).  With the exception
of lcI and RhaS (this study), evidence that s70 K593 directly contacts an activator has not
been obtained.  Our results indicate that s70 K593 contacts RhaS D250 as a part of the
mechanism of activation by RhaS (Fig. 6D).  Our molecular model of the RhaS-s70
interaction shows that s70 K593 and RhaS D250 are in close proximity, consistent with
this result (Fig. 4).  While the binary complex of Taq sA domain 4 and DNA shows that
the residue that corresponds to s70 K593 contacts DNA, in the lcI/s domain 4/DNA
ternary complex this residue participates in a protein-protein contact with lcI instead
(6, 19).  These findings indicate that s70 K593 is capable of interacting with an
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appropriately positioned transcription activator, and are consistent with our proposal
that s70 K593 may contact RhaS D250.
Comparison of transcription activation by RhaS and RhaR.  In this study we
have identified an interaction between RhaR D276 and s70 R599 that is equivalent to our
previously identified interaction of RhaS D241 and s70 R599.  Further, although a RhaR
equivalent of the RhaS D250 interaction with s70 K593 was not identified, our results do
not rule out that such an interaction occurs with RhaR.  Therefore, our current evidence
suggests that the RhaS-s70 interface is similar to the RhaR-s70 interface.  We certainly
expect, however, that not all aspects of RhaS activation and RhaR activation will be
identical.  For example, we know that the CRP site at rhaBAD is centered at position
–92.5, whereas the most important CRP site at rhaSR is centered at position –111.5.  It is
not possible to draw conclusions about how or whether differences in the RhaS-s70 and
RhaR-s70 interfaces might relate to this difference in CRP binding site position, since all
but one of the s70 derivatives tested were only defective in the absence of CRP.
However, it is likely that there is a difference in the mechanisms of RhaS and RhaR
activation that relates to this difference in the positions of the CRP binding sites.
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TABLE 1. Strains used in this study.
Strain, phage or
plasmid
Genotype Source or reference
E. coli strains
KM22 D(recC ptr recB recD)::Plac-bet exo kan (31)
ECL116 F- DlacU169 endA hsdR thi (2)
SME1074 ECL116 l SME106 Laboratory collection
SME1216 ECL116 l SME103 Laboratory collection
SME1851 ECL116 l SME104 Laboratory collection
SME2416 SME2417 zih-35::Tn10 Laboratory collection
SME2417 SME1216 D(recC ptr recB recD)::Plac-bet exo kan This study
SME2495 SME2417 DrhaSR::kan zih-35::Tn10 This study
SME2496 SME2416 DrhaSR::cat-sacB This study
SME2508 ECL116 l SME114 recA::cat Laboratory collection
SME2515 ECL116 l SME114 Laboratory collection
SME2608 SME1851 rhaS(wild-type) recA::kan Laboratory collection
SME2689 SME1851 rhaS(D250A) zih-35::Tn10 recA::kan This study
SME2691 SME2515 rhaR(D276A) zih-35::Tn10 recA::kan This study
SME2692 SME2515 rhaR(D285A) zih-35::Tn10 recA::kan This study
SME2693 SME2515 rhaR(wild-type) recA::kan This study
SME2800 SME1074 DrhaSR::kan zih-35::Tn10 This study
SME2933 SME2515 rhaR(E284A) zih-35::Tn10 recA::kan This study
Phage
lRS45 bla’-lacZsc att+ imm21 ind+ (40)
l SME103 l RS45 F(rhaB-lacZ)D110 (11)
l SME104 l RS45F(rhaB-lacZ)D84 (11)
l SME106 l RS45F(rhaS-lacZ)D216 (11)
l SME114 l RS45 F(rhaS-lacZ)D92 (17)
Plasmids
pGEX-2T s70 Apr rpoD wild-type (27)
pML148-169 pGEX-2T rpoD substitutions (27)
pSE101 pTZ 18R Apr rhaSR+rhaBA’ Laboratory collection
pSE172 Tetr pALTER-1 rhaS D250A Laboratory collection
pSE249 pSE101 rhaS D250A This study
pSE250 pUC18 rhaSRT’ wild-type This study
pSE251 pUC18 rhaSRT’ rhaR D276A This study
pSE252 pUC18 rhaSRT’ rhaR E284A This study
pSE253 pUC18 rhaSRT’ rhaR D285A This study
pSE254 pUC18 DrhaSR::cat-sac This study
pUC18 Apr lacZa (46)
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TABLE 2. Oligonucleotides used in this study.
Oligo.
No.
Oligonucleotide sequence, 5’-3’ Use
1170 CCGGAATTCTTGTGGTGATGTGATGCTCAC Amplify rhaSRT’ (within rhaBAD
promoter)
2068 ATGACCGTATTACATAGTGTGGAT IRD41 labeled - rhaS sequencing
2069 TTATTGCAGAAAGCCATCCCGTCC IRD41 labeled - rhaS sequencing
2074 TGGTTGCACAGATGGAACAGC IRD41 labeled - rhaS sequencing
2075 GTTGAGACGTGATGCGCTGTT IRD41 labeled - rhaS sequencing
2097 CGCGAATTCAAGGGTATGGTTTTGCAG Amplify rhaSRT from chromosome
(within rhaT promoter)
2204 GGTCACCGCGTGATATTCG IRD41 labeled - rhaR sequencing
2205 ATTCCGGGATTTAACGCCAG IRD41 labeled - rhaR sequencing
2206 TTAATCTTTCTGCGAATTGAG IRD41 labeled - rhaR sequencing
2207 CAAACGGCACATGCTGACTA IRD41 labeled - rhaR sequencing
2208 CGGTCGAAATTGCACTGATT rhaR D276A mutagenesis
2210 AATAGTTACTTGCTTCAAAGCCAC rhaR D285A mutagenesis
2292 CCTGGATCCCCGCAAAAGTGAA Amplify rhaSRT’ from plasmids
(within rhaT)
2297 GGTAAGATCTCGGTCATACTGGCCTCCTGATG Long-way around PCR to delete rhaSR
2298 GGTAAGATCTTTAATTCGCCATGCCGATGCCGA Long-way around PCR to delete rhaSR
2299 GGTAAGATCTCGGACCGGGTCGAATTTGC Amplify cat-sac cassette




aRegions of oligonucleotides not complementary to wild-type DNA sequence (encode restriction
endonuclease sites and flanking DNA or mutations) are underlined.
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FIGURE LEGENDS
Fig. 1.  Top: Representation of the divergent rhaSR and rhaBAD promoter regions
showing the approximate positions of the transcription activators RhaS, RhaR and CRP
as well as RNA polymerase at each promoter.  Bottom: Three consecutive lines of DNA
sequence extending from the rhaSR transcription start point to the rhaBAD transcription
start point.  Binding sites for RhaS, RhaR and CRP are shown by arrows and the –35 and
–10 hexamers of each promoter are indicated.  The upstream endpoints of promoter
fusions used in this study are marked “D”.  Deletion end points, protein binding sites,
and numbering relative to the rhaSR promoter are shown below the DNA sequence
while deletion end points, protein binding sites, and numbering relative to the rhaBAD
promoter are shown above the DNA sequence.
Fig. 2. Alanine substitutions within the C-terminal domain of the s70 subunit of RNA
polymerase assayed at two rhaS-lacZ fusions, F(rhaS-lacZ)D216 in SME1074 (A) and
F(rhaS-lacZ)D92 in SME 2508 (B).  The s70 alanine substitutions were encoded on
plasmids and the rhaS-lacZ fusions were in the chromosome as single-copy l lysogens.
In each panel, the values obtained with wild-type s70 were set to 100% and the activity
of each s70 derivative is represented as a percentage of the wild-type s70 value.  In panel
(A), the activity of wild-type s70 was 86 Miller Units for the I590A, R596A, L598A,
R603A, and R608A derivatives, while the wild-type s70 activity for the other derivatives
was 87 Miller Units.  In panel (B), the wild-type s70 activity was 3.6 Miller Units for the
I590A, R596A, L598A, R603A, and R608A derivatives and 2.2 Miller Units for the other
derivatives.
Fig. 3. Alignment of the amino acid sequences of the second helix-turn-helix DNA-
binding motifs of RhaS and RhaR.  Amino acids shown in black are those tested in this
work for possible interactions with the s70 subunit of RNAP.  Identical amino acids are
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indicated by vertical lines between the two sequences.  The boundaries of the first helix
(Helix 1), the turn, and the recognition helix (Helix 2) are based on the structure of
MarA (38) and alignments between MarA and RhaS and RhaR.  The numbers of the first
and last residues shown, as well as those of the residues tested for interactions with s70
are indicated.
Fig. 4. Model of RhaS or RhaR interactions with s70 domain 4.  The model of the RhaS or
RhaR C-terminal domain (aqua) is based on the crystal structure of the MarA-DNA
complex (38), while the model of s70 domain 4 (yellow) is based on the crystal structure
of the same domain of sA from Thermus aquaticus on DNA (6).  Only the DNA from the
MarA structure is shown (white).  Amino acid residues in RhaS or RhaR and s70 that are
implicated in interactions are shown in space filling model and labeled, with the RhaS
or RhaR residues colored red and the s70 residues colored dark blue.  The unlabeled
space filling residues are RhaR E284 (pink), RhaR D285 (which is at the same position as
RhaS D250), and s70 R608 (light blue).  Since s70 sits in front of RhaS or RhaR when the
DNA is shown parallel to the page, the model has been rotated somewhat around the
vertical axis to allow a view between the interacting proteins.  The modeling was
performed using the program Insight II by first manually superimposing the DNA’s in
the pdf files of MarA on DNA (1BL0) and sA domain 4 on DNA (1KU7) such that the
basepairs that corresponded to the –35 region of each were aligned as closely as
possible.  The sA model was then rotated to minimize clashes with MarA while
maintaining the DNA superimposition.  Finally, the residues implicated in interactions
were highlighted.  A second sA domain 4 molecule in the 1KU7 structure which does
not make specific contacts with the DNA is not shown.
Fig. 5. Transcription activation by RhaR derivatives.  b-Galactosidase activity was
assayed from a single copy fusion of the rhaSR promoter with lacZ that included the
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RhaR binding site but not the CRP binding sites (F(rhaS-lacZ)D92).  In each case, wild-
type RhaR or the alanine substitutions in RhaR were encoded in the chromosome at the
natural rhaR locus (strains SME2691, 2692, 2693, and 2933).  The value obtained with
wild-type RhaR (3.3 Miller units) was set to 100% and the activity of each RhaR
derivative was represented as a percentage of that value.
Fig. 6. Combinations of RhaR or RhaS derivatives with s70 derivatives.  Plasmid-
encoded s70 alanine substitutions were combined with chromosomally-encoded alanine
substitutions in RhaR or RhaS (strains SME 2689, 2691, 2692, 2693, and 2933) and b-
galactosidase activity was measured from F(rhaS-lacZ)D92 (A, B, C), or F(rhaB-lacZ)D84
(D).  The activity of wild-type s70 in combination with each RhaR or RhaS derivative in
Miller Units is shown on the corresponding bar in each graph, and was set to 100% in
each case.  This representation allows the relative defects of the s70 derivatives to be
directly compared.  The value for s70 K593A in combination with RhaR E284A was
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